The global infectious disease diagnostics market is witnessing robust growth, with projections estimating its value to rise from USD 26.58 billion in 2025 to USD 42.20 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.7% during the forecast period. This expansion is driven by the increasing prevalence of infectious diseases worldwide and the ongoing investments in research and development (R&D) for innovative diagnostic solutions.
With the rise in infectious disease cases globally, healthcare providers are placing greater emphasis on reliable and efficient diagnostic tools. Early detection and accurate diagnosis are critical for timely treatment, effective disease management, and improved patient outcomes. This trend has catalyzed the development of advanced diagnostic technologies, particularly those designed for rapid, decentralized testing, enabling broader access to actionable health insights.
To know about the assumptions considered for the study download the pdf brochure
Key Developments and Strategic Moves
The infectious disease diagnostics landscape has seen notable strategic activities by leading players aimed at expanding their technological capabilities and market presence. In July 2024, F. Hoffmann-La Roche Ltd. (Switzerland) acquired LumiraDx’s (US) infectious disease technology, enhancing Roche’s ability to offer decentralized patient care solutions and provide timely diagnostic results globally.
In November 2023, Abbott (US) received US FDA approval for its Alinity m High Risk (HR) HPV assay, strengthening its molecular testing portfolio and reinforcing its commitment to delivering accurate and accessible diagnostic solutions.
These moves highlight the growing importance of innovation and strategic partnerships in maintaining competitiveness in the infectious disease diagnostics market.
Leading Players Shaping the Market
Several multinational companies dominate the infectious disease diagnostics market, leveraging advanced technologies, extensive distribution networks, and strategic growth initiatives:
- F. Hoffmann-La Roche Ltd. (Switzerland) – Renowned for its molecular and immunoassay solutions, Roche maintains a robust global distribution network and leverages acquisitions and partnerships to sustain market leadership.
- Abbott (US) – Offers both centralized laboratory systems and rapid point-of-care testing, enhancing diagnostic accessibility across global markets.
- Danaher Corporation (US) – Supported by subsidiaries such as Cepheid and Beckman Coulter, Danaher provides automated, scalable diagnostic platforms for high-throughput infectious disease testing.
- bioMérieux (France) – Focuses on clinical microbiology and syndromic testing, providing advanced solutions for pathogen identification and antimicrobial resistance monitoring.
- Thermo Fisher Scientific Inc. (US) – Supplies molecular diagnostics, laboratory instruments, and workflow automation solutions essential for diverse healthcare settings.
Other notable participants in the market include Siemens Healthineers AG (Germany), Becton Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India).
Market Leadership and Strategic Approaches
- Hoffmann-La Roche Ltd. holds a prominent position due to its comprehensive molecular and immunoassay solutions, strong regulatory expertise, and global reach. The company employs a combination of direct and indirect distribution channels, allowing it to navigate demand fluctuations across regions. In addition, Roche strategically leverages mergers, acquisitions, and partnerships to consolidate its market position and expand its global footprint.
Danaher Corporation maintains a strong market presence through its diversified diagnostic portfolio and extensive global operations. Its subsidiaries, including Cepheid and Beckman Coulter, allow Danaher to address a broad spectrum of infectious disease testing requirements. The company emphasizes inorganic growth strategies, such as collaborations and strategic agreements, to enhance technological capabilities and strengthen its position in high-growth diagnostic segments.
Future Outlook
As the global demand for accurate and timely infectious disease diagnostics continues to rise, companies are focusing on innovation, global expansion, and strategic partnerships. Emerging trends include the adoption of rapid point-of-care testing, integration of molecular and immunoassay techniques, and the use of digital platforms for data analysis and workflow optimization.
The infectious disease diagnostics market is poised for substantial growth, fueled by ongoing advancements in technology, increasing investments in R&D, and a global healthcare landscape increasingly focused on early disease detection and improved patient outcomes.
This growth trajectory underscores the importance of sustained innovation, robust distribution networks, and strategic initiatives, which collectively position leading players to meet the evolving needs of the healthcare sector.